Vanguard Capital Management
LYEL icon

Vanguard Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Vanguard Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
786,774
+68,619
+10% +$1.24M ﹤0.01% 2753
2026
Q1 		$14.4M Buy
+718,155
New +$16.8M ﹤0.01% 2526

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Vanguard Capital Management's LYEL Position: Q2 2026 in Review

Vanguard Capital Management increased its Lyell Immunopharma (LYEL) stake by 9.6% in Q2 2026, buying an estimated $1.24M and bringing the position to 786,774 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2753.

Vanguard Capital Management first reported a position in LYEL in Q1 2026 and has held it in 2 quarters since. The position peaked at $14.4M in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Vanguard Capital Management held 786,774 shares of Lyell Immunopharma worth $11.1M as of Q2 2026.
  • Vanguard Capital Management bought 68,619 Lyell Immunopharma shares in Q2 2026, an estimated $1.24M.
  • Lyell Immunopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2753 holding.
  • Vanguard Capital Management first reported a position in Lyell Immunopharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Lyell Immunopharma position peaked at $14.4M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.